Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , could represent a notable advancement for obesity treatment. Preliminary human investigations have indicated impressive losses in abdominal tissue, potentially outperforming other weight-loss treatments. Neverthel